• Vaccine Name: H107
• Target Pathogen: Mycobacterium tuberculosis
• Target Disease: Tuberculosis
• Type: Subunit vaccine
• Status: Research
• Host Species for Licensed Use: Mouse
• Antigen: H107 is a recombinant fusion protein composed of eight Mycobacterium tuberculosis antigens, including PPE68, ESAT-6 (four repeats), EspI, EspC, EspA, MPT64, MPT70, and MPT83 (Woodworth et al., 2021).
• EsxA (ESAT-6) gene engineering:
  • Type: Fusion Protein
  • Description: This is use for fusion protein preparation (Woodworth et al., 2021).
  • Detailed Gene Information: Click Here.
• PPE68 gene engineering:
  • Type: Fusion Protein
  • Description: This is use in fusion protein preparation (Woodworth et al., 2021).
  • Detailed Gene Information: Click Here.
• espI gene engineering:
  • Type: Fusion Protein
  • Description: This is use in fusion protein preparation (Woodworth et al., 2021).
  • Detailed Gene Information: Click Here.
• espC gene engineering:
  • Type: Fusion Protein
  • Description: This is use in fusion protein preparation (Woodworth et al., 2021).
  • Detailed Gene Information: Click Here.
• espA gene engineering:
  • Type: Fusion Protein
  • Description: Use in fusion protein preparation (Woodworth et al., 2021).
  • Detailed Gene Information: Click Here.
• MPT64 gene engineering:
  • Type: Fusion Protein
  • Description: This is use in fusion protein preparation (Woodworth et al., 2021).
  • Detailed Gene Information: Click Here.
• mpt70 gene engineering:
  • Type: Fusion Protein
  • Description: This is use in fusion protein preparation (Woodworth et al., 2021).
  • Detailed Gene Information: Click Here.
• MPT83 gene engineering:
  • Type: Fusion Protein
  • Description: Use in fusion protein preparation (Woodworth et al., 2021).
  • Detailed Gene Information: Click Here.
• Adjuvant: CAF01 vaccine adjuvant
  • Adjuvant name: CAF01 vaccine adjuvant
  • VO adjuvant ID: VO_0005483
  • Description: CAF®01 (DDA + TDB) is the adjuvant use to promote Th1/Th17-biased cellular immunity (Woodworth et al., 2021).
• Preparation: The H107 antigen was produced as a recombinant multi-antigen fusion protein and formulated with the CAF®01 adjuvant, a cationic liposome system composed of DDA and TDB, prior to subcutaneous administration (Woodworth et al., 2021).
• Immunization Route: subcutaneous injection

Mouse Response

• Host Strain: CB6F1 and B6C3F1
• Vaccination Protocol: Mice were immunized three times subcutaneously with H107 formulated in CAF®01 at two-week intervals, either alone or co-administered with a single BCG vaccination (Woodworth et al., 2021).
• Challenge Protocol: Vaccinated mice were challenged with aerosolized Mycobacterium tuberculosis Erdman strain, and lung bacterial burden was measured at 4 and 18 weeks post-infection (Woodworth et al., 2021).
• Efficacy: H107 alone provided protection superior to BCG, and co-administration of BCG with H107 resulted in synergistic and sustained reduction in lung bacterial burden (Woodworth et al., 2021).
• Information about this animal model: Mouse Model for TB research